

# BUSINESS STANDARD 15<sup>th</sup> DECEMBER, 2017

	2017	2016	2015	2014
3. Exceptional and / or Extraordinary (Items) Net Profit/(Loss) for the period before tax (After Exceptional and / or Extraordinary Items)	(1.82)	0.86	(7.37)	27.93
4. Net Profit / (Loss) for the period after tax (after exceptional and / or Extraordinary Items)	(1.82)	0.86	(7.37)	27.93
5. Total Comprehensive Income for the period (Comprising profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax))	(1.82)	0.81	(7.37)	10.48
6. Equity Share Capital	324.90	324.90	324.90	324.90
7. Reserve (including Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	Nil	Nil	Nil	Nil
8. Earnings per share (of Rs. 10/- each) (for continuing and discontinued operations) -				
1. Basic	(0.30)	0.07	(0.23)	0.80
2. Diluted	(0.30)	0.07	(0.23)	0.80

**Note:**  
1. The above is an extract of the detailed format of Statement of Standalone Un-audited financial results filed with the BSE Limited under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial results and this extract were reviewed by the audit committee and approved at the meeting of the Board of Directors of the company at the meeting held on 13.12.2017. The full format of the Statement of Standalone Un-audited financial results is available on the Company's website ([www.combatdrugs.in](http://www.combatdrugs.in)) and on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)).  
2. A Limited Review as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been completed on the detailed financial results for the quarter ended 30th September, 2017 filed with the BSE Limited. This report does not have any impact on the Results and Notes for the Quarter ended 30th September, 2017.

Place: Hyderabad  
Date: 14-12-2017

K. Omprakash  
Whole Time Director

	2017	2016	2015	2014
3. Exceptional and / or Extraordinary (Items) Net Profit/(Loss) for the period before tax (After Exceptional and / or Extraordinary Items)	(6.82)	2.14		
4. Net Profit / (Loss) for the period after tax (after exceptional and / or Extraordinary Items)	(6.82)	2.14		
5. Total Comprehensive Income for the period (Comprising profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax))	(6.82)	2.14		
6. Equity Share Capital	528.25	528.25		
7. Reserve (including Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	Nil	Nil		
8. Earnings per share (of Rs. 10/- each) (for continuing and discontinued operations) -				
1. Basic	(0.13)	0.03		
2. Diluted	(0.13)	0.03		

**Note:**  
1. The above is an extract of the detailed format of Statement of Standalone Un-audited financial results filed with the BSE Limited under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial results and this extract were reviewed by the audit committee and approved at the meeting of the Board of Directors of the company at the meeting held on 13.12.2017. The full format of the statement of standalone financial results is available on the Company's website ([www.springsoft.com](http://www.springsoft.com)) and on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)).  
2. A Limited Review as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been completed on the detailed financial results for the quarter ended 30th September, 2017 filed with the BSE Limited. This report does not have any impact on the Results and Notes for the Quarter ended 30th September, 2017.

Place: Hyderabad  
Date: 14-12-2017

**COMBAT DRUGS LIMITED**  
9-10/9, PLOT NO.112, ROAD NO-14, GAYATRI NAGAR, BODUPPAL, R.R.DISTRICT-506 030, TELANGANA  
(CIN NO. CL32337GTG1R6PLC306781), URL: [www.combatdrugs.in](http://www.combatdrugs.in), Mail: [info@combatdrugs.in](mailto:info@combatdrugs.in)

**EXTRACT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2017**  
(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended		Half year Ended
		30.09.17	30.09.16	30.09.17
1.	Total Income from Operations (Net)	22.90	9.85	26.49
2.	Net Profit / Loss for the period before Tax (before Extraordinary items)	12.33	(5.82)	4.55
3.	Net Profit / Loss for the period before Tax (After Extraordinary items)	12.33	(5.82)	4.55
4.	Net Profit / Loss for the period after Tax (After Extraordinary items)	12.33	(5.82)	4.55
5.	Total Comprehensive Income for the period	12.33	(5.82)	4.55
6.	Equity Share Capital	800	800	800
7.	Reserves	-	-	-
8.	Basic & Diluted Earning per Share (of Rs. 10/- each)	-	-	-
i.	Basic	0.15	(0.07)	0.06
ii.	Diluted	0.15	(0.07)	0.06

**Notes:**  
1. The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the stock exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results along with limited Review Report are available on the Stock Exchange Website [www.bseindia.com](http://www.bseindia.com) and on Company's website [www.combatdrugs.in](http://www.combatdrugs.in).  
2. Previous years / period's figures have been regrouped / rearranged / repeated wherever necessary.  
3. The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14th December, 2017.

By order of the Board  
For Combat Drugs Limited  
Sd/-  
Suchit Mohan Lal  
Managing Director

Place: Hyderabad  
Date: 14.12.2017

Jay SPEAK



The Art of boardroom

Business Standard  
Insight Out

To book your copy call 022 24878470 or SMS [www.businessstandard.com](http://www.businessstandard.com) to 56677 or

**IOFL**  
India Infoline Finance Limited

CIN: U67120MH2004PLC147365  
Corporate & Regd. Office: 12A-10, 13th Floor, Parinee C  
C-38 & 39, G-Block, Bandra Kurla Complex, Bandra (East),

**PUBLIC NOTICE OF AUCTION OF GOLD ORNAMENTS**

Notice is hereby given to the general public that, due to non-regularization of gold loan accounts by the Borrowers in respect of Gold Loan Account numbers from, GL1521723, GL1789642, GL6714515, GL6780040, GL6820761, GL6882455, GL6886677, GL6886861, GL6889319, GL6893912, GL6895844, GL6896123, GL6896872, GL6897122, GL6897275, GL6897668, GL6904983, GL6905595, GL6905754, GL6907473, GL6908303, GL6909003, GL6909243, GL6910186, GL6910719, GL6911206, GL6911332, GL6911361, GL6911882, GL6912403, GL6915144, GL6915906, GL6915945, GL6918968, GL6920055, GL6920248, GL6920888, GL6922486, GL6922665, GL6922915, GL6923074, GL6924940, GL6925710, GL6925984, GL6933570, GL6934972, GL6935355, GL6935403, GL6935543, GL6936423, GL6936562, GL6937778, GL6938710, GL6938848, GL6938868, GL6939089, GL6942410, GL6942486, GL6945256, GL6945553, GL6945904, GL6946222, GL6947234, GL6947435, GL6947646, GL6947789, GL6947866, GL6949116, GL6949142, GL6951700, GL6953874, GL6954683, GL6954953, GL6955395, GL6960722, GL6960758, GL6963218, GL6965007, GL6965656, GL6967953, GL6967815, GL6971482, GL6972308, GL6973883, GL6975883

NAVA TELANGANA 15<sup>th</sup> DECEMBER, 2017

హైదరాబాద్  
15 డిసెంబర్ 2017

**సాక్షి**  
వినియోగదారుల నిర్దేశించిన ఉత్తమ వాణిజ్య సంస్థగా గుర్తింపుగా ఉన్న అభివృద్ధి కీమ్ కోంగ్ ఉస్ అన్నాడు. ఇది సాంకేతికతను అభివృద్ధి చేయడానికి కృషి చేస్తుంది. ప్రపంచ దేశాలకు గత చరిత్ర తెలుసుకుని అన్నాడు కొరియా ద్వీపకల్పంలో ఉన్న ఉత్తమ ఉత్పాదక శ్రమ కుటుంబంగా నిరూపించారు.

**COMBAT DRUGS LIMITED**  
9-109/9, PLOT NO.112, ROAD NO.14, GAYATRI NAGAR, BOOUPPAL, R.R.DISTRICT-506 039, TELANGANA  
(CIN NO. CL232310T01986PLC036781), URL: www.combatdrugs.in, Mail: info@combatdrugs.in

**సాంకేతికత** (రూ. లక్షల్లో)

	అర్ధవార్షిక మొత్తం	
	30-09-2017	30-09-2016
16	2,082.83	4,385.57
26	(457.37)	(257.44)
3)	(457.37)	(257.44)
3)	(457.37)	(257.44)
3)	(457.37)	(257.44)
8	491.08	491.08
	(9.32)	(5.24)
	(9.32)	(5.24)

ఈ మొత్తం ఆదేశాలను అర్థిక ఫలితం  
www.bseindia.com మరియు కంపెనీ  
సైట్లో అందుబాటులో ఉంచబడుతుంది.  
సహకారం కోసం ధన్యవాదాలు.  
అధ్యక్షుడు  
అధ్యక్షుడు

**COMBAT DRUGS LIMITED**  
9-109/9, PLOT NO.112, ROAD NO.14, GAYATRI NAGAR, BOOUPPAL, R.R.DISTRICT-506 039, TELANGANA  
(CIN NO. CL232310T01986PLC036781), URL: www.combatdrugs.in, Mail: info@combatdrugs.in

EXTRACT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2017

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended		Half year Ended
		30.09.17	30.09.16	
1.	Total Income from Operations (Net)	22.90	9.85	26.49
2.	Net Profit / Loss for the period before Tax (before Extraordinary items)	12.33	(5.82)	4.55
3.	Net Profit / Loss for the period before Tax (After Extraordinary items)	12.33	(5.82)	4.55
4.	Net Profit / Loss for the period after Tax (After Extraordinary items)	12.33	(5.82)	4.55
5.	Total Comprehensive Income for the period	12.33	(5.82)	4.55
6.	Equity Share Capital	800	800	800
7.	Reserves	-	-	-
8.	Basic & Diluted Earning per Share (of Rs.10/- each)	-	-	-
i.	Basic	0.15	(0.07)	0.06
ii.	Diluted	0.15	(0.07)	0.06

**Notes:**

- The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the stock exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results along with limited Review Report are available on the Stock Exchange Website www.bseindia.com and on Company's website www.combatdrugs.in
- Previous year's / period's figures have been regrouped / rearranged / recasted wherever necessary.
- The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14th December, 2017.

By order of the Board  
For Combat Drugs Limited  
Sd/-  
Suchit Mohan Lal  
Managing Director

Place: Hyderabad  
Date: 14.12.2017

**MOSCHIP SEMICONDUCTOR TECHNOLOGY LIMITED**  
హైదరాబాద్, టెలంగాణ రాష్ట్రం, పోస్ట్ కోడ్ 500 084, ప్లాట్ నెం. 112, గాయత్రీ నగర్, రైల్వే కాలనీ, హైదరాబాద్-506 039  
Ph: 040-66229292 Fax: 040-66229303  
CIN: L31909TG1999PLC032184

30 సెప్టెంబర్, 2017లో ముగిసిన త్రిమాసికం ఓ ఆరు నెలలకు ఆదితీయాని స్టాండింగ్ లోన్ అర్హత ఫలితాలు

(రూ. లక్షల్లో)

వివరాలు	మూడు నెలలకు		ఆరు నెలలకు		2017 ఆదితీయాని ముగిసిన సంవత్సరం	
	30-Sep-17 ఆదితీయాని	30-Jun-17 ఆదితీయాని	30-Jun-16 ఆదితీయాని	30-Sep-17 ఆదితీయాని		
అదనపు సుంకీ షార్ట్ అండ్ లాంగ్ (పెటెంట్)	1,450.89 (128.77)	1,280.18 (213.97)	719.90 36.07	2,710.87 (342.74)	1,022.88 50.80	3,944.34 (32.12)
పెటెంట్ అనుబంధం	(128.77)	(213.97)	35.96	(342.74)	50.69	118.88
పెటెంట్ అనుబంధం (అనుబంధం అనుబంధం)	2,506.25	2,497.37	2,275.85	2,506.25	2,275.85	2,497.37
కాపీరైట్లు (గత సంవత్సరం యొక్క క్యాంపెయిన్లలో)	NA	NA	NA	NA	NA	6,115.4